BioCentury
ARTICLE | Clinical News

BHCG-VAC: Phase II discontinued

August 8, 2011 7:00 AM UTC

Celldex disclosed in its 2Q11 earnings that in June it discontinued an open-label, U.S. Phase II trial comparing neoadjuvant therapy with CDX-1307 plus cisplatin and gemcitabine vs. cisplatin and gemcitabine alone prior to surgical resection in about 30 patients with newly diagnosed hCG-beta expressing muscle-invasive bladder cancer. The decision was based on the company's prioritization of resources to focus on lead programs. Celldex said it plans to further develop the compound in investigator-sponsored studies. ...